Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Cardiovascular Disease (CVD)

FDA Requests Removal of Pregnancy Contraindication for Statins

Brian Park, PharmD

July 23, 2021

The FDA conducted a comprehensive review of all available data associated with the use of statins during pregnancy.

Anemia

Generic Version of Feraheme Now Available

Brian Park, PharmD

July 20, 2021

The first generic version of Feraheme (ferumoxytol injection) has been made available by Sandoz.

Bladder Cancer

Padcev Gets Full Approval, Expanded Indication for Urothelial Cancer

Brian Park, PharmD

July 15, 2021

Full approval was granted based on overall survival data from a confirmatory trial.

Chronic Kidney Disease (CKD)

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

Brian Park, PharmD

July 14, 2021

The approval was based on data from the phase 3 FIDELIO-DKD trial.

Chronic Kidney Disease (CKD)

Soaanz Approved for Edema With Heart Failure, Renal Disease

Brian Park, PharmD

June 28, 2021

Soaanz is a loop diuretic with an extended duration of action lasting approximately 6 to 8 hours.

Kidney Stones

Generic Version of Thiola Now Available

Brian Park, PharmD

May 19, 2021

Tiopronin is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria who are unresponsive to treatment with high fluid intake, alkali, and diet modification.

Urinary Tract Infections (UTI)

Vaginal pH Regulator Gets Fast Track Status for Gonorrhea Prevention

Brian Park, PharmD

May 18, 2021

EVO100 is pH-modulating vaginal gel designed to reduce certain vaginal infections by balancing vaginal pH, thereby maintaining healthy vaginal flora.

Diabetic Nephropathy

Finerenone Improves Cardiovascular Outcomes in Patients With Diabetic Kidney Disease

Brian Park, PharmD

May 13, 2021

The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.

Anemia

FDA Approves Single Dose Option for Iron Replacement Therapy Injectafer

Brian Park, PharmD

May 7, 2021

For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously.

Chronic Kidney Disease (CKD)

Bardoxolone Under Review for CKD Caused by Alport Syndrome

Brian Park, PharmD

April 30, 2021

The NDA submission includes data from the phase 3 CARDINAL trial that evaluated the efficacy and safety of bardoxolone in 157 patients with CKD caused by Alport syndrome.

Next post in Chronic Kidney Disease (CKD)